Researchers at the moment are asking whether or not GLP-1 medication akin to Ozempic and Mounjaro may ultimately grow to be a part of the remedy toolkit.
And that is notably related in India.
Practically 1 in 5 younger Indian ladies might have PCOS, in response to figures cited by specialists in a 2025 PTI report. Globally, the situation impacts about 1 in 8 ladies, in response to the 2026 worldwide evidence-based guideline on PMOS.
PCOS is not merely about having cysts on the ovaries.
In actual fact, the situation’s new identify — Polyendocrine Metabolic Ovarian Syndrome — displays its broader hormonal, metabolic and reproductive results.
For a lot of ladies with PMOS, insulin resistance is a vital a part of the situation.
Consider insulin as a key that opens the door for sugar to enter your cells, the place it may be used for vitality.
With insulin resistance, that key would not work correctly. So the physique compensates by producing extra insulin to get the identical job performed.
And in some ladies with PMOS, that extra insulin can stimulate the ovaries to provide extra androgens, or male hormones, disrupting ovulation and intervals and contributing to signs akin to pimples and extra facial hair.
That is the place GLP-1 medication get fascinating.
These medicines will help with weight reduction and blood sugar management, whereas weight reduction itself can enhance a few of the metabolic issues related to PMOS.
However the query of whether or not they can even enhance reproductive outcomes is way much less settled.
In a small proof-of-concept evaluation revealed in Fertility and Sterility in June 2026, researchers led by Melanie G Cree examined ladies with PMOS utilizing semaglutide.
Of the 11 ladies who accomplished the evaluation, eight misplaced a minimum of 10% of their physique weight. Median weight reduction was about 19 kg, whereas androgen ranges fell by 52%. Six ladies reported extra frequent intervals, and 4 reported returning to month-to-month cycles.
The researchers described the findings as early proof and cautioned that bigger, longer-term research are wanted to determine whether or not the reproductive advantages are sustained.
That is an essential caveat.
Whereas the broader proof is encouraging, notably round weight and metabolic well being, whether or not GLP-1 medication can persistently enhance ovulation, intervals or fertility remains to be being studied.
The 2026 worldwide PMOS guideline says anti-obesity medicines akin to semaglutide might have a job in managing weight and metabolic well being in some ladies with PMOS, however notes that proof on their reproductive results stays restricted.
Weight-loss medication are already utilized in India for diabetes and weight problems, and researchers at the moment are analyzing whether or not their advantages may prolong to ladies with PMOS, notably those that even have extra weight or metabolic issues.
However as of now, GLP-1 medication should not established therapies particularly accepted for PMOS.
So this is not about saying Ozempic can remedy PCOS.
The larger query is whether or not GLP-1s may ultimately grow to be one other instrument to deal with a few of the metabolic issues related to PMOS — and probably a few of its reproductive penalties too.
For the hundreds of thousands of Indian ladies coping with the situation, that is a narrative value watching.
